TLPPF:OTC-Telix Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 18.065

Change

0.00 (0.00)%

Market Cap

USD 6.05B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 42.38B
UCBJY UCB SA ADR

N/A

USD 39.56B
UCBJF UCB SA

N/A

USD 39.40B
GNMSF Genmab A/S

N/A

USD 14.30B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 12.58B
WXIBF WuXi Biologics

N/A

USD 12.52B
AKESF Akeso, Inc.

N/A

USD 8.30B
IVBIY IVBIY

N/A

USD 7.97B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.81B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.77B

ETFs Containing TLPPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.63% 65% D 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.63% 65% D 76% C+
Trailing 12 Months  
Capital Gain 127.23% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 127.23% 93% A 93% A
Trailing 5 Years  
Capital Gain 2,409.03% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,409.03% 98% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 103.04% 74% C 84% B
Dividend Return 103.04% 74% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 117.96% 43% F 31% F
Risk Adjusted Return 87.35% 99% N/A 96% N/A
Market Capitalization 6.05B 96% N/A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.